Industry Insights · Artificial Heart & Circulatory Support
Percutaneous RVAD enters the 'green channel': the overlooked right heart and a harder materials problem
While LVADs held the spotlight, right-heart support always lagged; its entry into the fast track brings the overlooked right-heart-failure need back into view.
The overlooked right heart
Percutaneous left-ventricular assist advanced fast and filled a domestic gap; but heart failure was never only left-sided. By incidence, China sees roughly 90,000 new acute right-heart-failure cases a year — the right heart needs support too.
Why RVADs arrived late
The first barrier is the venous-blood environment: slow flow, easy stasis and higher clotting risk demand stricter hemocompatibility. Percutaneous hearts already chase higher hemocompatibility and longer service life; the right heart adds difficulty on top, raising the bar on motor, bearing and integration design.
What the green channel means
Entering the special review for innovative devices means the product's innovation and clinical value are recognized and review support is closer — likely speeding the path to market.
The BIO angle
FAQ
Why is right-heart support harder than left?
The right heart faces venous blood — slow flow, easy stasis, higher clotting risk — demanding stricter hemocompatibility; with high motor, bearing and integration requirements, the barrier is higher.
What is the 'green channel'?
China's special review for innovative devices, giving products of clear clinical value and innovation closer review interaction and a likely faster path to market.
How large is China's right-heart-failure need?
By incidence, about 90,000 new acute right-heart-failure cases a year — a long-underestimated clinical need.
Related reading
- Carmat Aeson Total Artificial Heart: Design and Materials of the EU's Only Commercial TAH | BIO Insights
- China's Maglev Artificial Heart: from First Implant to the Global High-End Market | BIO Insights
- The Artificial-Heart 'First IPO' Race: Revenue Up Three Years, Yet Years of Losses | BIO Insights
Note: an original analysis compiled from public industry information; figures and conclusions per official/original sources. Not investment advice.
Building in China's medical-device market?
From advanced medical silicone/polymers to material selection, regulatory and supply, BIO helps global and local partners move from selection to landed supply in China.